This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by North, T. W.
Right arrow Articles by Barry, P. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by North, T. W.
Right arrow Articles by Barry, P. A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2004, p. 2760-2765, Vol. 48, No. 7
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.7.2760-2765.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Rhesus Cytomegalovirus Is Similar to Human Cytomegalovirus in Susceptibility to Benzimidazole Nucleosides

Thomas W. North,1,2* Getachew Sequar,1,3 Leroy B. Townsend,4 John C. Drach,4,5 and Peter A. Barry1,3

Center for Comparative Medicine,1 Department of Veterinary Molecular Biosciences,2 Department of Medical Pathology, University of California, Davis, Davis, California 95616,3 Interdepartmental Graduate Program in Medicinal Chemistry, College of Pharmacy,4 Department of Biologic and Materials Sciences, School of Dentistry, University of Michigan, Ann Arbor, Ann Arbor, Michigan 481095

Received 6 November 2003/ Returned for modification 8 January 2004/ Accepted 15 March 2004

Rhesus and human cytomegalovirus (RhCMV and HCMV, respectively) exhibit comparable inhibition by benzimidazole nucleosides, including 2,5,6-trichloro-(1-ß-D-ribofuranosyl)benzimidazole (TCRB), and pyrrolo[2,3-d]pyrimidines. The two HCMV protein targets of TCRB, UL89 and UL56, are highly conserved with their RhCMV homologues. These data indicate that infection of rhesus macaques with RhCMV represents a useful model to test novel anti-HCMV drugs.

* Corresponding author. Mailing address: Center for Comparative Medicine, University of California, Davis, Davis, CA 95616. Phone: (530) 752-3414. Fax: (530) 752-7914. E-mail: twnorth{at}ucdavis.edu.

Antimicrobial Agents and Chemotherapy, July 2004, p. 2760-2765, Vol. 48, No. 7
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.7.2760-2765.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Yue, Y., Kaur, A., Eberhardt, M. K., Kassis, N., Zhou, S. S., Tarantal, A. F., Barry, P. A. (2007). Immunogenicity and Protective Efficacy of DNA Vaccines Expressing Rhesus Cytomegalovirus Glycoprotein B, Phosphoprotein 65-2, and Viral Interleukin-10 in Rhesus Macaques. J. Virol. 81: 1095-1109 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»